Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17692101rdf:typepubmed:Citationlld:pubmed
pubmed-article:17692101lifeskim:mentionsumls-concept:C1442914lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0678236lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0599921lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C1367654lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0024651lld:lifeskim
pubmed-article:17692101lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:17692101pubmed:issue4lld:pubmed
pubmed-article:17692101pubmed:dateCreated2007-9-14lld:pubmed
pubmed-article:17692101pubmed:abstractTextIntestinal marginal zone B-cell lymphoma of the MALT type (I-MZL) is a relatively uncommon form of lymphoma. Twenty-seven patients with histologically-confirmed I-MZL were analyzed. The patients initially presented with abdominal pain (62.9%), and diarrhea (22.2%). The most common involved site was the ileo-caecal area (40.7%). Musshoff's stage I(E), II(E)1, II(E)2, III(E) and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively. Sixty-three percent were in the low-risk group according to the Follicular Lymphoma International Prognostic Index. Complete response and partial response were achieved in 82% and 4% patients. The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54%. Stage > or = II(E)2 was determined to be a poor prognostic factor for PFS and OS. I-MZL commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis. I-MZL tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site MZLs.lld:pubmed
pubmed-article:17692101pubmed:languageenglld:pubmed
pubmed-article:17692101pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17692101pubmed:citationSubsetIMlld:pubmed
pubmed-article:17692101pubmed:statusMEDLINElld:pubmed
pubmed-article:17692101pubmed:monthOctlld:pubmed
pubmed-article:17692101pubmed:issn0902-4441lld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KimJung HanJHlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:RyooBaek-Yeol...lld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KimKihyunKlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KimWon SeogWSlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:NamEunmiElld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KimHyo-JinHJlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:OhSung YongSYlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:LeeJae-HoonJHlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KwonHyuk-Chan...lld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:ParkYeon...lld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KangHye JinHJlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:HwangIn GyuIGlld:pubmed
pubmed-article:17692101pubmed:authorpubmed-author:KoYoung HaeYHlld:pubmed
pubmed-article:17692101pubmed:issnTypePrintlld:pubmed
pubmed-article:17692101pubmed:volume79lld:pubmed
pubmed-article:17692101pubmed:ownerNLMlld:pubmed
pubmed-article:17692101pubmed:authorsCompleteYlld:pubmed
pubmed-article:17692101pubmed:pagination287-91lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:meshHeadingpubmed-meshheading:17692101...lld:pubmed
pubmed-article:17692101pubmed:year2007lld:pubmed
pubmed-article:17692101pubmed:articleTitleIntestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.lld:pubmed
pubmed-article:17692101pubmed:affiliationDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.lld:pubmed
pubmed-article:17692101pubmed:publicationTypeJournal Articlelld:pubmed